Advertisement

Topics

Latest "Tilray Stock Major Short Squeeze Underway" News Stories

16:29 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Tilray Stock Major Short Squeeze Underway" found in our extensive news archives from over 250 global news sources.

More Information about Tilray Stock Major Short Squeeze Underway on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tilray Stock Major Short Squeeze Underway for you to read. Along with our medical data and news we also list Tilray Stock Major Short Squeeze Underway Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tilray Stock Major Short Squeeze Underway Companies for you to search.

Showing "Tilray Stock Major Short Squeeze Underway" News Articles 1–25 of 18,000+

Saturday 23rd March 2019

Henry Avocado Recalls Whole Avocados Because of Possible Health Risk

Henry Avocado Corporation is voluntarily recalling California-grown whole avocados sold in bulk at retail stores because they have the potential to be contaminated with Listeria monocytogenes. Henry Avocado is issuing this voluntary recall out of an abundance of caution due to positive test results on environmental samples taken during a routine government...


Verastem Cancer Therapy Should Get Traction, Raise Stock Price

Innovent Starts US Trial of "Pivotal" CD47 Immunotherapy

Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling pathway, inhibit the "do not eat me" signal, and promote the phagocytosis of tumor cells by macrophages. Innovent called IBI188 a "pivotal product in ou...


Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons

Friday 22nd March 2019

Overdominance is the major genetic basis of lint yield heterosis in interspecific hybrids between G. hirsutum and G. barbadense

SeqOnce Biosciences Launches RhinoSeq™ Rapid DNA Library Preparation Kit

SeqOnce Biosciences Inc. launches its new RhinoSeq™ DNA Library Preparation Kit for Next Generation Sequencing (NGS) sample preparation. PASADENA, Calif. (PRWEB) March 22, 2019 SeqOnce Biosciences Inc. launches its new RhinoSeq™ DNA Library Preparation Kit for Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit chemistry that makes it the fastest DNA librar...

Low-loss solution at short wavelengths

What Tilray Thinks About The 'Farming Business' And Why The Company May Need To Raise More Capital Soon

Commentary on “The point-of-care Bilistick method has very short turn-around-time and high accuracy at lower cut-off levels to predict laboratory-measured TSB.”

Genome-Wide Association Study of Major Agronomic Traits in Foxtail Millet (Setaria italica L.) Using ddRAD Sequencing

[Comment] Prevention of decompensation in cirrhosis: a new youth for β blockers

The natural history of cirrhosis can be described as a continuum from a compensated phase to decompensation and liver failure, marked by the development of ascites, overt hepatic encephalopathy, or variceal haemorrhage, occurring at a rate of 5–7% per year. This decompensation results in an increased mortality, and a median survival of 2 years versus 12 years in the compensated phase.1 Hepatic f...

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to ...

WuXi AppTec Reports Strong 2018 Annual Results

Revenue RMB9,614 Million, up 23.8% (25.4% at Constant Exchange Rate) Year-Over-Year Net Profit Attributable to Owners of the Company RMB2,261 Million, up 84.2% Year-Over-Year Diluted EPS RMB 2.21, up 70.0% Year-Over-Year SHANGHAI, March 22, 2019 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 0235...

FDA Approves Ketamine Derivative as Depression Treatment for First Time

Treatment-resistant depression affects 1 in 3 of the estimated 16.2 million adults in the U.S. who have suffered at least one major depressive episode. For them, two or more therapies have failed and the risk of suicide is much greater. It’s a grim prognosis. There are few therapies for depression that resists treatment, which is why the FDA granted this new drug application Fast Track and Brea...

FitLife Brands Announces 2018 Results

FitLife Brands, Inc. (“FitLife”) (OTC Pink: FTLF), an international provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (

Gossamer Bio Announces 2018 Annual Financial Results

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments. ...

Novartis to spin off Alcon

FDA Turns Down Sotagliflozin for Type 1 Diabetes

Advisory panel had expressed major concerns about diabetic ketoacidosis. Medscape Medical News

resTORbio Announces Closing Public Offering of Common Stock

resTORbio (NASDAQ:TORC) has announced the closing of a previously announced underwritten public offering of 7.2 million shares of its common stock at a price of US$6.95 per share. As quoted in the press release:  resTORbio also granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common stock at the … Continued The post resTORbio Announces Closing Pub...

Antidepressant drugs may not work when neurons are out of shape

elective serotonin reuptake inhibitors are the most commonly prescribed medication for major depressive disorder, yet scientists still do not understand why the treatment does not work in nearly thirty percent of patients with MDD.

Fugitive air-pollutant releases from Calif. refineries, associated risk to people exposed, covered in new report

The below Mar. 20, 2019 news release is from the California Environmental Protection Agency Air Resources Board. California air quality regulators today [Mar. 20, 2019] released a report recommending actions to improve emergency and routine air

Over 3,000 more pharmacists needed in general practice to tackle GP shortages, says think tank report

A minimum of 3,000 extra pharmacists are needed in general practice across England by 2024 to help tackle rising patient demand and GP shortages, a report compiled by three major think-tanks warns.

Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision

FDA commissioner discloses effort underway to tighten oversight of changes to active pharmaceutical ingredient manufacturing processes by rewriting parts of...   

Long-term use of inexpensive weight-loss drug may be safe and effective

An inexpensive weight-loss drug approved 60 years ago for only short-term use also may be safe and effective for longer-term treatment, according to a study conducted by researchers at Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning network.

Apple: hoher Short-Anteil wegen negativem Sentiment!

New York (www.aktiencheck.de) - Apple-Aktienanalyse von Analyst Jim Suva von der Citigroup: Jim Suva, Analyst bei der Citigroup, bestätigt laut einer Aktienanalyse seine Kaufempfehlung für die Akti...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks